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Developing a new antimicrobial conipound in the near 
future will likely be more challenging for companies 
and investigators than in the past. Just demonstrating 
that the drug is as effective as a reference antibiotic will 
probably not be enough anymore. 
The new drug will have to be either more efficient, 
less toxic, less expensive, or have a lower negative effect 
upon microbial ecology. The development process of 
cefepime has been, in part, designed in this way. Several 
characteristics of the drug are important and some 
recent studies loolung at the effects of different cephalo- 
sporins upon resistance could anticipate what kind of 
studies could be needed in the future to demonstrate 
any advantage that a new drug has over the huge 
number of already available agents. Cefepiine has 
several potential advantages. It penetrates bacteria very 
quickly and is more stable to inducible cephalo- 
sporinases. However, during randomized, multicenter 
clinical trials (RCTs), even with a large number of 
patients, it is very difficult to demonstrate that those 
kinds of characteristic bring a clinical or a bacteriologic 
benefit. Most of the studies comparing cefepinie to 
comparators such as ceftazidinie [1,2] have shown 
similar results. The results were slightly better in 
Beaucaire’s study in patients with a bacteriologically 
proven pneumonia, but this represents only a subgroup. 
However, it  should he noted that most early trials 
followed FDA trial design criteria, including only 
patients with infections due to microorganisnis suscep- 
tible to all agents used in both arms of the trial. 
A trend for the superiority of cefepime plus metro- 
nidazole over iniipeneni appears, even after adjustment 
for severity, in the study from Barie et al [3] but the 
dosage of the comparative drug (imipenem) was rather 
low (500 mg/6 11). 
Again, the ‘ecological’ benefit of a drug is difficult 
to show easily during RCTs and studies with a specific 
design have to be organized to answer this question. 
Two studies have been performed looking at the trends 
in the resistance to cephalosporins after a switch from 
ceftazidime to cefepime [4,5]. Those two studies show 
a sharp decrease in the resistance to ceftazidinie, with- 
out any significant increase in the resistance to cefepinie. 
We have to establish a direct and logical link between 
the change in antibiotic policy and the mechanism of 
resistance which is targeted, and be sure, for example, 
that the resistance to Enterobacterixeae in those two 
studies is really due to cephalosporinases and not to 
other mechanisms such as extended- spectrum p- 
lactamases, in the spread of which cross-transmission is 
the key parameter. 
Of course, those preliminary results have to be 
confirmed in prospective, randomized studies, but the 
concept is fascinating. More generally, it is likely that 
antibiotic ‘cycling’ could be an  interesting tool to help 
control resistance to antibiotics [6,7]. The paper from 
Struelens et a1 in this supplement raises a series of 
fascinating questions and methodological issues to be 
solved ifwe want to demonstrate the ‘ecological’ impact 
of an antibiotic strategy. 
It  is also important to try to understand why several 
antibiotics could generate a lower antibiotic pressure 
than others. The impact of the drugs on the intestinal 
flora is undoubtedly the most important and easiest 
target to look at. The role of the digestive flora is key, 
especially in the intensive care unit. In some ways, the 
digestive tract represents a connection between the 
patient and the environment. Microorganisms such as 
MRSA or .4cinetobactcr spp., as well as, Pstwdomorzas spp. 
and Enterobacteriaceae, are present in the digestive 
tract of ICU patients. 
Thus, the digestive tract and probably to a lesser 
extent the airway of mechanically ventilated patients 
serve as occult, hidden ‘factories’, amplifying resistance 
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to antibiotics, especially inducible cephalosporinases. 
Thus, it is key to look at the effects of different 
antibiotics not only upon the microorganisms present 
at the site of infection, but also upon those present 
within the bronchial and digestive flora, to better 
understand relationships between trends in resistance 
and antibiotic policies. 
We have many fascinating areas to look at! For 
example, cycling does not necessarily imply (at least in 
my mind) the use of a given antibiotic for a long period 
of time and then switching. It is a philosophy, a way to 
avoid antibiotic monotony and the periodicity of the 
cycles can be very short. The different papers gathered 
in this supplement provide the background for future 
studies. They open the doors, helping people to think 
‘differently’ and to design new studies to look seriously 
and scientifically at the ecological and environmental 
effect of antibiotics, which will certainly be the most 
fascinating challenge in the next few years for new 
antibiotic compounds. 
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